Javid Moslehi

He is a cardiologist and myocyte biologist. his clinical focus is cardio-oncology (the cardiovascular care of cancer patients and cancer survivors). His basic and translational NIH-funded laboratory addresses myocardial responses to various stresses including hypoxia, aging and toxins. Over the last several years, given his clinical interest in cardio-oncology, his laboratory focus has been in delineating the mechanistic underpinnings of cardiovascular toxicities from novel targeted cancer therapies. He believes because of the targeted nature of the toxicities, cardio-oncology can provide insights into novel signalling pathways that are relevant in human cardiovascular biology and pathology.

At Vanderbilt, He is an Associate Professor of Medicine, Director of Cardio-Oncology and Co-director of Vanderbilt Program for Optimizing Immuno-oNcology Therapy (V-POINT). He works closely with cardiologists and oncologists, basic, translational researchers and clinicians locally, nationally and internationally. He has also started several collaborations with industry and regulatory bodies (including the US FDA). He was recently named the first chair of the American Heart Association (AHA) cardio-oncology subcommittee. At Vanderbilt, he has established a Graduate Medical Education (GME) approved fellowship training the next generation of physician-scientists in the field of cardio-oncology. He is an elected member of American Society of Clinical Investigation (ASCI).